Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of Fulcrum Therapeutics Inc (NASDAQ: FULC) was $7.82 for the day, down -1.14% from the previous closing price of $7.91. In other words, the price has decreased by -$1.14 from its previous closing price. On the day, 0.57 million shares were traded. FULC stock price reached its highest trading level at $8.03 during the session, while it also had its lowest trading level at $7.63.
Ratios:
Our analysis of FULC’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.86 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 55.84. For the most recent quarter (mrq), Quick Ratio is recorded 28.71 and its Current Ratio is at 28.71. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
On May 15, 2025, Cantor Fitzgerald Upgraded its rating to Overweight which previously was Neutral but kept the price unchanged to $10.
H.C. Wainwright Downgraded its Buy to Neutral on September 13, 2024, whereas the target price for the stock was revised from $17 to $4.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 08 ’25 when Tourangeau Greg sold 498 shares for $5.06 per share. The transaction valued at 2,520 led to the insider holds 14,062 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FULC now has a Market Capitalization of 422118144 and an Enterprise Value of 203620176. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.28 while its Price-to-Book (P/B) ratio in mrq is 1.85. Its current Enterprise Value per Revenue stands at 2.545 whereas that against EBITDA is -22.787.
Stock Price History:
The Beta on a monthly basis for FULC is 2.48, which has changed by -0.11936939 over the last 52 weeks, in comparison to a change of 0.16564083 over the same period for the S&P500. Over the past 52 weeks, FULC has reached a high of $10.13, while it has fallen to a 52-week low of $2.32. The 50-Day Moving Average of the stock is 11.06%, while the 200-Day Moving Average is calculated to be 72.75%.
Shares Statistics:
FULC traded an average of 633.18K shares per day over the past three months and 447620 shares per day over the past ten days. A total of 53.98M shares are outstanding, with a floating share count of 47.85M. Insiders hold about 11.36% of the company’s shares, while institutions hold 85.53% stake in the company. Shares short for FULC as of 1751241600 were 5638853 with a Short Ratio of 8.91, compared to 1748563200 on 5681558. Therefore, it implies a Short% of Shares Outstanding of 5638853 and a Short% of Float of 15.100000999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current assessment of Fulcrum Therapeutics Inc (FULC) involves the perspectives of 8.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.64, with high estimates of -$0.27 and low estimates of -$3.1.
Analysts are recommending an EPS of between -$0.99 and -$1.22 for the fiscal current year, implying an average EPS of -$1.15. EPS for the following year is -$1.21, with 8.0 analysts recommending between -$1.04 and -$1.43.
